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Where do we draw the line?Thoralf M. Sundt III, MDDuring the past decade, there has been increasing attention
to the risk of aortic complications associated with bicuspid
aortic valve (BAV) disease. BAV is a curious experiment
of nature in the biology of aortic aneurysmal disease and,
therefore, has been the subject of considerable scientific in-
vestigation. It iswidely recognized that BAVdisease is a her-
itable condition transmitted in an autosomal dominant
fashion with incomplete penetrance.1,2 The occurrence of
an associated aortopathy independent of functional valve
disease is also well documented.3-7 Although the
associated aneurysmal dilatation of the ascending aorta
has been thought by many to be a hemodynamic effect,
analogous to post-stenotic dilatation, it is increasingly rec-
ognized that this is an inherent abnormality of the aorta.8
Significant ascending aortic enlargement is present in
30% to 60% of patients with BAV, and in many instances,
particularly when BAV is associated with aortic insuffi-
ciency, the aortic valve annulus is significantly enlarged,
as may be the sinuses of Valsalva.5,9-11
It has also long been recognized that patients with BAV
are overrepresented in autopsy studies of dissection, mak-
ing up as many as 10% of these individuals.12 Because
BAV is thought to occur in the general population at a fre-
quency of 1%, this is a significant overrepresentation. Of
note, the diameter of these BAV-associated aortas before
dissection is, of course, unknown. In addition, progressive
enlargement of the ascending aorta after aortic valve
replacement has been documented,13 as has excess long-
term mortality among patients undergoing aortic valve
replacement for bicuspid disease compared with trileaflet
valves.14 Accordingly, an increasingly aggressive approach
to the surgical replacement of the ascending aorta at the
time of aortic valve replacement in the presence of BAV
has been advocated. Given the evidence from multiple
studies that aortic dissection may occur at dimensions
less than 5 cm, including among patients with BAV, current
American College of Cardiology/American Heart Associa-
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The Journal of Thoracic and Carreplacement at the time of aortic valve replacement for
BAV if the ascending aorta exceeds 4.5 cm with the subtle
assumption that in experienced hands this can be accom-
plished at little incremental risk.15
The more difficult question arises among patients whose
BAV is functioning well, but who demonstrate only moder-
ate degrees of aortic dilatation. At what diameter does the
aorta itself become an indication for surgical repair? There
is broad agreement for all patients with ascending aortic an-
eurysms that aortic dilatation to 6 cm or greater strongly
supports surgical repair, and an almost unanimous view
that surgical intervention is prudent at a diameter of 5.5
cm.16 Some have advocated earlier repair at 5 cm to provide
an additional margin of safety. But what about dimensions
less than 5 cm? At what point do we draw the line? When
does the treatment become worse than the disease?
The implications of ever lower diameter criteria for re-
placement of the ascending aorta associated with BAV are
profound. Given an incidence of 1% among the 300 million
citizens living in the United States today, any recommenda-
tion regarding the ascending aorta in the presence of BAV
affects an enormous number of individuals.17 Beyond the
statistical impact, the emotional force is great as well. As
anxiety concerning the risk of dissection among patients
with only moderate dilatation of the ascending aorta in-
creases, more women of child-bearing age women come
to medical attention asking about the safety of pregnancy.
Should a newlywed wishing to start a family and found to
have an ascending aorta of 4.5 cm be advised that it is unsafe
for her to do so? Is close cardiologicmonitoring satisfactory,
or is she prohibited from having children? Do the data really
support the notion that the risks of dissection are greater at
a given aortic diameter when associated with BAV?
To be sure, aortic dissection can occur among patients
with BAV at dimensions less than 5 cm, but the same is
true of the general population.18 But the mean diameter of
the ascending aorta progressing to dissection in the setting
of BAV in the study by Svensson and colleagues19 was 6
cm, just what we would expect from the general population.
Why do we have so much difficulty in drawing the line
between the aorta that can be monitored and the aorta that
needs to be replaced? Of course, one problem is the inescap-
able paradox of making a binary decision in the face of
a continuous gradient of risk. Beyond this, there are at least
3 complicating issues: the numerator/denominator problem,
the difference between probability and statistics, and the
seemingly irresistible urge to equate BAV with Marfan
syndrome.diovascular Surgery c Volume 140, Number 6S S41
FIGURE 1. Calculating the risk of dissection requires knowledge of both the numerator and denominator.
FIGURE 2. Bayes’ Theorum as applied to prediction of the probability of
dissection given a bicuspid aortic valve. BAV, Bicuspid aortic valve.
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is surely alarming, it is also true that the majority of patients
have aortas smaller than 5 cm. To calculate the risk of aortic
complications, we need not only the numerator, which is to
say the cases that come to medical or surgical attention, but
also the vast denominator of patients who live happily with-
out complications (Figure 1). Our efforts to screen the public
reveal ‘‘disease’’ among this vast denominator, but the clin-
ically relevant question is: What is their risk of complica-
tions, and does it exceed the operative risk for ascending
aortic replacement? The same numerator/denominator prob-
lem is evident in the location of traffic accidents; the major-
ity, likely more than 50%, occur within 5 miles of home,
whereas less than 20% occur more than 20 miles from
home. But is it really safer to drive on the freeway? No:
We simply spend more time driving close to home—the de-
nominator is greater. As surgeons, we live in the numerator,
seeing only those patients who have had complications.
The next challenge is the relationship between statistics
and probability, which is to say the relationship between
the observed past and the predicted future. We know that,
given a dissection, the statistical frequency of BAV is 1 in
10. But given a BAV, what is the probability of future dissec-
tion? This is the difference between what we know and what
we want to know. The sample space for the former question
is all patients with dissection, whereas that for the latter is all
patients with BAV. Bayes’ Theorem of conditional probabil-
ity is helpful in estimating this risk given some assumptions
(Figure 2). The probability of acute dissection (disease)
given BAV (exposure) equals the product of the probability
of a BAV given acute dissection and the probability of
acute dissection divided by the probability of a BAV. If theS42 The Journal of Thoracic and Cardiovascular Surgprobability of BAV given acute dissection is 10% or 0.1,12
and the probability of acute dissection is 10 in 100,00020
with a population frequency of BAV 1% or 0.01, we would
estimate the probability of acute dissection given a BAV to
be 0.001 or 0.1%. Of course this would be the risk of the
natural history of the disease given all-comers with BAV,
without stratifying by aortic dimensions. Any prophylactic
treatment needs to be accomplished at lower risk than this.
Finally, what is the evidence supporting the analogy with
Marfan syndrome? There is no question that there are simi-
larities. Both are heritable conditions with associated inher-
ent aortic abnormalities. Elastin loss and fragmentation
have been observed in histologic specimens of patients
with aneurysms associatedwith both conditions,21 as has ap-
optosis of vascular smooth muscle cells.22 Furthermore, his-
tologic specimens have demonstrated a fibrillin deficiency23ery c December 2010
Sundt Aortic Symposium 2010and increased matrix metalloproteinases and decreased tis-
sue inhibitor of metalloproteinases.24-26 What is less clear
is the quantitative relationship between the 2. Nonetheless,
the urge to make the analogy between BAV disease and
Marfan syndrome seems irresistible. Numerous authors
have done so, and it is common to find the phrase ‘‘BAV
and Marfan syndrome’’ in discussions of aortic disease.
The surgical relevance of this analogy with Marfan syn-
drome is the recent trend to recommend earlier and earlier
surgical intervention among patients with the latter condi-
tion.27 Again, as in those without Marfan syndrome, dissec-
tion can occur in those with Marfan syndrome at aortic
diameters less than 5 cm.28 This, as well as the advent of
valve-sparing options, has encouraged an increasingly ag-
gressive approach such that root replacement is commonly
recommendedMarfan syndromewhen the aorta is 4.5 cm or
less.29 These recommendations, however, are based almost
exclusively on ‘‘expert opinion.’’
Is BAV comparable to Marfan syndrome? Only a small
number of studies have been performed evaluating the nat-
ural history of ascending aortic aneurysms in the setting of
BAV. Among those that have been done, there is scant evi-
dence of a significantly increased risk of rupture or dissec-
tion among thosewith small aortas. Furthermore, in contrast
with Marfan syndrome, data suggest that supracoronary
graft replacement of the ascending aorta, leaving behind
the sinuses of Valsalva, seldom leads to root aneurysms
(Park, unpublished data, 2010). Finally, data from the
Mayo Clinic concerning patients undergoing aortic valve
replacement for BAV demonstrate overall survival remark-
ably similar to that predicted for the general population
(McKellar, unpublished data). This is in marked contrast
with the natural history of unoperated Marfan syndrome,
for which the average age of death is approximately 30
years.30 Clearly 1% of the population is not dying at
a mean age of 30 years secondary to BAV aortopathy and
rupture. Indeed, the most common indication for surgical
intervention among patients with BAV in an Olmsted
County community-based study was aortic valve replace-
ment, not aortic replacement.31 Finally, if one reviews the
data presented by the International Registry of Dissection,
the frequency of BAVamong patients with acute dissection
is approximately comparable to Marfan syndrome despite
BAV being 100 times more common.18
Although surgeons strive to be evidence-based, we are
experience-driven. This can lead to faulty reasoning as we
practice on the basis of heuristics, not science. The evidence
that BAV is a risk factor for dissection independently of aor-
tic size is scant. BAV is not Marfan syndrome.References
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